Antimicrobial Agents and Chemotherapy · 2019 · 114 citations · 22 references
MedicinePharmacologyPharmacotherapyAntimicrobial PharmacotherapyClinical PharmacologyOrthopedicsAntibacterial PharmacotherapyBone InfectionsJoint InfectionsOrthopedic InfectionOsteomyelitisSeptic ArthritisAntibiotic Penetration Into BoneAntibiotic-loaded ImplantsBone Infection TherapyGram-positive Bacterial InfectionsImplant-associated Infection TreatmentJoint Infection TherapyOral Antibiotic TherapyProduct Safety Profile
were the most frequent microorganisms. The reasons for switching to dalbavancin were simplification (53.1%), adverse events (25%), or failure (21.9%). There were 7 adverse events, and no patient had to discontinue dalbavancin. In 45 cases, infection was related to an orthopedic implant. The implant material was retained in 23 cases, including that in 15 (65.2%) patients that were classified as cured and 8 (34.8%) that presented improvement. In 21 cases, the implants were removed, including those in 16 (76.2%) cases that were considered successes, 4 (19%) cases were considered improved, and 1 (4.8%) case that was considered a failure. Among the 19 cases without implants, 14 (73.7%) were considered cured, 3 (15.8%) were considered improved, and 2 (10.5%) were considered failures. The results show that dalbavancin is a well-tolerated antibiotic, even when >2 doses are administered, and is associated with a high cure rate. These are preliminary data with a short follow-up; therefore, it is necessary to gain more experience and, in the future, to establish the most appropriate dose and frequency.
22
Douglas R. Osmon, Elie F. Berbari, Anthony R. Berendt et al. · Clinical Infectious Diseases · 2012 · 2.2K citations · Full text
Jaime Lora-Tamayo, Óscar Murillo, José Antonio Iribarren et al. · Clinical Infectious Diseases · 2012 · 390 citations